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Objectives. This studv was conducted to elucidate the role of the
adenosine triphosphate (ATP)-sensitive potassium channel block-
ing agent glibenclamide and the opener cromakalhn in the mech-
anism of repe.rfusion-induced injury .
Background. Recently, ATP-sensitive potassium channel open-
en have bun proposed to reduce ischemia/reperfusion--induced
injury, including arrhythinias and heart function . Thus, one
might hypothesize that pharmacologic agents that enhance the loss
of potassium ions in the myocardium through ATP-sensitive
potassium channels would be arehythmogenic, and agents that
interfere with tissue potassium ion loss would be antiarrhythmic .
Meh'. ods. Isolated "working" guinea pig hearts and phospho-
rus-31 nuclear magnetic resonance spectroscopy were used to
study the recovery of n,wardW1 function and phosphorus com-
pounds
after 30, 40 and 50 min of normothermic global ischemil
followed by reperfusion in untreated control and glibenclamide-
and cromakalim-treated groups .
Results. After 30 min of ischetnia, 1, 3, 10 and 30 pmol/liter
of glibenclamide dose-dependently reduced the incidence of
reperfusion-induced ventricular fibrillation (total) from its control
In drug prophylaxis against cardiac death, there are at least
two absolute requirements for any new agent that determine
therapeutic potential : 1) the drug must prevent fatal arrhyth-
mias (e.g ., ventricular fibrillation), and 2) the drug must have
few side effects . The significance of such alterations in
electrophysiology during ischemia/reperfusion was ad-
dressed in recent studies (1,2) that reported that adenosine
triphosphate (ATP).-sensitive potassium channel opening
agents increased the potential for the development of ven-
tricular fibrillation in a subset of postinfarction animals that
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value of 921b to
7591, 33% (p '0
0 .05) 9 33% (p < 0.05) and 42%a
(p < 0.05), respectively . The incidence of ventricular tachyc2rdia
followed the same pattern. A reduction of arrhythmias was also
observed after 40 and 50 min of ischemia followed by reperfusion
in the glibenclamide-treated hearts. Cromakalim, at the some
concentrations, did not reduce the incidence of reperfusion-
induced arrhythunins. During reperfusion, glibenclamide (3 and
10 pinol/liter) improved the recovery of coronary blood flow,
aortic flow, myocardial contractility and tissue ATP and creative
phosphate content, but cromakalim failed to ameliorate the recov-
ery of postischemic myocai-dium compared with that in the
drug-free control hearts .
Conclusions. The preservation of myocardial potassium ions
and phosphorus compounds by glibenclamide can improve the
recovery of postischemic function, but the use of ATP-sensitive
potassium channel openers as antihypertensive or antiarrhythmic
agents may be of particular concern in those postinfarction
patients who are known to be at high risk for sudden cardiac
death .
(J Am (MY Wbi 1994;23 :487 96)
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otherwise show low risk for the development of lethal
arrhythmias . It was stated that the increased vulnerability of
the heart to develop ventricular fibrillation was associated
with the ATP-sensitive potassium channel opener-induced
reduction in the ventricular refractory period . This conclu-
sion is consistent with the known action of ATP-sensitive
potassium channel openers, whereby they enhance potas-
sium efflux during myocardial repolarization and decrease
the duration of the action potential . Conversely, in isolated
preparations, potassium channel openers have been found to
decrease delayed afterde polarizations, early afterdepolariza-
tions, and depolarization-induced and triggered activity
(3,4) . Despite the putative antiarrhythmic action, these drugs
may exacerbate various forms of arrhythmias . In isolated
dog Purkinje fibers a curious form of tachycardia was
observed using high concentrations of ATP-sensitive potas-
sium channel openers (5) . In whole heart experiments both
proarrhythmic and antiarrhythmic actions have been de-
scribed for ATP-sensitive potassium channel openers in
various models and species (6-8), whereas glyburide, an
0735-1097194/$7 .00
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ATP-sensitive potassium channel blocking agent, protected
the heart against ischemia and reperfusion arrhythmias (6,9) .
Any rational approach to the development of therapy
against reperfusion-induced arrhythmias requires that the
relative importance of substances that are responsible for
arrhythmogenesis be identified
. For any candidate at least
two critical questions must be answered : 1) Does the sub-
stance play an independent role in arrhythmogenesis? and 2)
Does the substance play the principal or pivotal role in
arrhythmogenesis? Recently, many studies have been di-
rected to elucidating the role of potassium in the pathophys-
iology during myocardial ischemia and reperfusion . There-
fore the present study focused on the particular candidates,
the ATP-sensitive potassium channel openers and blockers,
that can regulate myocardial potassium status . Our aim was
to show the effects of cromakalim and glibenclamide on the
incidence of arrhythmias, heart function and myocardial
metabolism in ischemia/reperfused hearts. Furthermore, to
-our knowledge, the relation between ATP sensitive potas-
sium channel openers and blockers and myocardial ATP and
creative phosphate content has not been studied . Therefore
phosphorus-31 nuclear magnetic resonance (NMR) spectros-
copy was used to provide a unique opportunity to investigate
the metabolic effects of alterations in the myocardium with-
out the tissue sampling required for biochemical assays .
Methods
n technique . All animals received care in compli-
ance with the principles of laboratory animal care formulated
by the National Society for Medical Research and the guide
for the care and use of laboratory animals prepared by the
National Academy of Sciences and published by the Na-
tional Institutes of Health (Publication No, NIH 80-23,
revised 1978). Male guinea pigs weighing 350 to 400 g were
anesthetized with intraperitoneal pentobarbital sodium
(60 mglkg body weight) and then given intravenous heparin
(500 Mkg). After thoracotomy, the heart was excised and
placed in ice-cold perfusion buffer . Immediately after prep-
aration, the aorta was cannulated, and the heart was per-
fused according to the Langen;!orff< method for a 5-min
washout period at a constant perfusion pressure equivalent
to 100 cm of water (10 kPa). The perfusion medium consisted
of a modified Krebs-Henseleit bicarbonate buffer ([milli-
molar concentration] sodium chloride 118 . potassium chlo-
ride 5.8, calcium chloride 1 .8, sodium bicarbonate 25, so-
dium biphosphate 0 .36. magnesium sulfate 1 .2 and glucose
5.5). The Langendorif preparation was switched to the
working mode, as previously described in detail by Neely et
al. (10) and modified by Yamamoto et al . (11) . Aortic flow
was measured by a calibrated rotameter . Coronary flow
rate was measured by timed collection of the coronary
perfusate that dripped from the heart.
Measurement of rhythm disturbances . The electrocardio-
gram (ECG) was analyzed for the incidence of ventricular
fibrillation and ventricular tachycardia and whether the
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fibrillation was nonsustained (spontaneously reverting to
regular rhythm) or sustained (persisting throughout the
reperfusion period) . The heart was considered to be in
ventricular fibrillation if an irregular, undulating baseline
was present on the ECG . Ventricular tachycnrdia was de-
fined as five or more consecutive premature ventricular
complexes, and this classification included ventricular flutter
and repetitive monomorphic ventricular tachycardia, which
is difficult to dissociate from rapid ventricular tachycardia . If
the regular sinus rhythm did not return during the I st 10 min
of reperfusion, ventricular fibrillation was considered sus-
tained ventricular fibrillation .
Phosphorus-31 NMR spectroscopy . Phosphorus-31 (31p)
NMR spectroscopy was used as described in detail else-
where (12-14) . Essentially, phosphorus-31 NMR spectros-
copy was performed on a Bruker CXP-200 wide-bore, ver-
tically positioned spectrometer (Bruker Medical Instrument)
operating at a phosphorus frequency of 90 .98 MHz by
applying 45" sampling pulses with a 2-s repetition time .
Ninety free-induction decay signals were obtained by means
of an 8K memory block, and signals were exponentially
multiplied with a line-broadening factor of 10 to 20 Hz and
were Fourier transformed to produce NMR spectra in the
400-Hz spectral range . Thus, each NMR result represented
an average of the 3-min sampling periods . The following
phosphorus compounds were observed : inorganic phos-
phate, creatine phosphate and three peaks of ATP where the
beta-peak was considered to be specific for ATP (15) . After
the experiment, the data were analyzed, and the integral of
peak areas was used for the assessment of relative concen-
trations of the various substances . Intracellular pH was
estimated on the basis of the chemical shift of the inorganic
phosphate signal (16) . Acidification of the intracellular milieu
induced by ischemia led to an upfield shift of inorganic
phosphate toward the creatine phosphate peak . As a refer-
ence for spectra quantitation . I -amino- I -phenyl.niethylene
diphosphonate was used .
Experimental time course and heart function studies . Im-
mediately after excision of the heart (n = 12 in eacl. group),
the aorta was cannulated, and Langendorff perfusion was
initiated for a 5-min washout period . During this time an
incision was made in the pulmonary artery to ensure the
ejection of coronary effluent, and the left atrium was cannu-
lated. The heart was then converted to the "working mode"
for 15 min. During the 1st 5 min, control values for heart
rate, coronary flow, aortic flow, left ventricular developed
pressure (defined as the difference between left ventricular
systolic and end-diastolic pressures), maximal first deriva-
tive of left ventricular developed pressure (dP/dt max) and
left ventricular end-diastolic pressure were recorded . After
5 min of "working" control perfusion, the heart was per-
fused for another 10 min with different concentrations of the
drugs, and myocardial heart function was registered . At
the end of the 15-min aerobic period, the atrial and aortic
cannulas were clamped, and the heart was subjected to 30,
40 or 50 min of normothermic global ischemia . At the end of
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Figure 1 . Dose-response studies of the ability of glibenclamide to
reduce reperfusion-induced ventricular fibrillation (VF) (A) and
ventricular tachycardia (VT) (B) . Hearts (n = 12 in each group) were
subjected to 30 min of normothermic global ischemia followed by
reperfusion . Glibenclamide was included in the perfusion fluid
throughout the experimental period in various concentrations . Re-
sults were compared with findings in drug-free control hearts . The
incidence (%) of ventricular fibrillation (A) during reperfusion is
shown as total ventricular fibrillation (sustained plus nonsustained)
(hatched bars) and sustained ventricular fibrillation (open bars) .
Comparisons were made with the drug-free values . *p < 0.05 .
the ischemic period, each heart was initially reperfused at
37°C in the Langendorff mode for 10 min . Flectricai defibril-
lation was not used in any hearts . At the end of Langendorif
reperfusion, hearts were converted to the working mode for
an additional 20 min, and during this time, the recovery of
heart function was recorded in nonfibrillating hearts .
Statistics. Adenosine triphosphate, creatine phos,hate,
pH and variables of heart function were expressed as mean
value ± SEM. A one-way analysis of variance was first
carried out to test for any differences in mean values between
groups . If differences were established, the values of the
drug-treated groups were compared with those of the un-
treated ischemic group by means of the modified t test . An
analogous procedure was followedd for distribution of dis-
crete variables, such as the incidence of ventricular fibrilla-
tion and ventricular tachycardia . An overall chi-square test
for the 2 x n table was constructed, followed by a sequence
of the 2 x 2 chi-square test to compare individual groups .
Results
eperfusion-induced arrhythmias . The results (Fig . 1)
illustrate that after 30 min of global ischemia followed by
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Figure 2. Dose-response studies of the ability of cromakalim to
reduce reperfusion-induced ventricular fibrillation (A) and ventricu-
lar tachycardia
(B). Hearts (n = 12 in each group) were subjected to
30 min of normothermic global ischemia followed by reperfusion .
Cromakalim was included in the perfusion buffer throughout the
experimental period in various concentrations
. Results were com-
pared with findings in drug-free control hearts
. Abbreviations and
symbols as in Figure I
.
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reperfusion (n = 12 in each group), glibenclamide affords a
dose-dependent antiarrhythmic effect . Thus, with glibencla-
mide concentrations of 1, 3, 10 and 30 Amol/liter, the total
ventricular fibrillation (sustained
Flt's
nonsustained) wa!,
reduced (Fig. IA) from its control, drug-free value of 92% to
75% (p = NS), 33% (p < 0.05), 33% (p < 0 .05) and 42% (p <
0.05)
. respectively
. The corresponding values for sustained
ventricular fibrillation were 92% (control) versus 67% (p =
NS), 25% (p < 0 .05), 33% (p < 0 .05) and 33% (p < 0.05),
respectively (Fig
. IA). The incidence of ventricular tachy-
cardia (Fig . 113) showed a tendency toward a dose-
dependent reduction, and the changes achieved a level of
statistical significance
. Cromakalim at concentrations of I to
30 /Amol/liter failed to reduce the incidence of reperfusion-
induced ventricular fibrillation and ventricular tachycardia
(Fig. 2, A and B) .
Heart function studies . In this
study, hearts were sub-
jected to 30, 40 or 50 min of global ischemia followed by
reperfusion. On reperfusion, after 30, 40 and 50 min of
ischemia, the incidence of reperfusion-induced ventricular
fibrillation was 89%, 75% and 50%, respectively, in the
drug-free group (calculated from Tables I to 3)
. Because
cardiac function (heart rate, aortic flow, left ventricular
developed pressure and left ventricular dP/dt max) can be
studied in nonfibrillating hearts only, Tables 1 to 3 show how
many hearts were needed to be studied to obtain n = 12
~ 0 Sustained CIF
ToYaO VF
*Myocardial function can be measured only in nonfibrillating hearts
. The
total number of hearts indicates how many hearts were needed to obtain 12
nonfibrillating hearts in each group
. Because of the high incidence of ventric-
ular fibrillation (VF) in the control and cromakplim-treated groups, a maxi-
mum of 120 hearts was studied (total number of hearts) in these
groups . SR
ins rhythm .
nonfibrillating hearts in the control and glibenclamide- and
cromakalim-treated groups . Glibenclamide significantly re-
duced the incidence of reperfusion ventricular fibrillation com-
pared with control values . Therefore, in the glibenclamide-
treated groups, the total number of hearts studied was
reduced to obtain 12 nonfibrillating hearts for the registration
of myocardial function (Tables I to 3) . In hearts treated with
cromakalim, a reduction in the incidence of reperfusion-
induced arrhythmias was not observed. Thus, using 10 and
30,umolAiter of cromakalim, all hearts showed reperfusion-
induced ventricular fibrillation (Tables I to 3), which made it
impossible to measure myocardial function in these groups .
The high incidence of reperfusion arrhythmias refers to the
Table 2. Number of Hearts Entered Into the Study After 40 min
of Normothermic Global Ischemia Followed by 30 min
of Reperfusion*
*Myocardial function can be measured only in nonfibrillating hearts . The
total number of hearts indicates how many hearts were needed to obtain 12
nonfibrillating hearts in each group
. Because of the high incidence of ventric-
ular fibrillation (VF) in the control and cromakalim-treated groups, a maxi-
mum of 50 hearts was studied in these groups
. SR = sinus rhythm .
*Myocardial function can be measured only in nonfibrillating hearts
. The
total number of hearts indicates how many hearts were needed to obtain 12
nonfibrillating hearts in each group . All hearts were in ventricular fibrillation
(VF) in 6e cromakalim-treated groups receiving 10 and 30 pmolifiter .
Therefore, heart function was not recorded
. A maximum of 30 hearts was
studied in each g roup . SR = sinus rhythm .
previously reported proarrhythmic action of ATP-sensitive
potassium channel openers (1,2,17,18) .
In the untreated group (Table 4), after 30 min of global
ischemia followed by 30 min of reperfusion, heart rate,
coronary flow, left ventricular developed pressure and left
ventricular dP/dt max returned to preischemic values, but
aortic flow was at a very low level (39 .0 ± 1 .4 ml/min [before
ischemia] vs . 13.5 ± 1 .4 ml/min [after ischemia]) . The
relative increase in left ventricular end-diastolic pressure
was elevated after 30 min of ischemia followed by 30 min of
reperfusion (0.1 ± 0.02 kPa [before ischemia] vs . 0 .8 ± 0.05
kPa [after ischemia]) in the drug-free control group . After 40
and 50 min of global ischemia followed by 30 min of
reperfusion, all functional variables, except coronary flow,
failed to reach preischemic values . Thus, coronary flow recov-
ered to 22.1 ± 1 .1 and 20.0 ± 0.8 ml/min, respectively, from the
preischemic control value of 21 .0 ± 1 .5 ml/min. In hearts
treated with I jumol/liter of glibenclamide (Table 4), in myocar-
dial function variables did not differ compared significantly
from time-matched control values . Three and 10 lzmol/liter of
glibenclamide significantly improved the recovery of left ven-
tricular developed pressure and left ventricular dP/dt max after
40 and 50 min of global ischemia and reduced the relative
elevation of left ventricular end-diastolic pressure (Table 4) .
When the concentration of glibenclamide was increased to
30 pmolAiter (Table 4), myocardial function variables were
worsened before ischemia (after drug administration) and after
30, 40 and 50 min of ischerniaa followed by reperfusion .
In hearts treated with I and 3 jAmol/liter of cromakalim
(Table 4), a significant increase in coronary flow rate was
measured before ischernia and during reperfusion, but other
variables of cardiac function were not improved . Because of
the high incidence of ventricular fibrillation (100%, pro-
arrhythmic action), in hearts treated with 10 and 30 jumolI
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Table 1
. Number of Hearts Entered Into the Study After 30 min
of Normothermic Global Ischemia Followed by 30 min
of Reperfusion*
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Table 3
. Number of Hearts Entered Into the Study After 50 min
of Normothermic Global Ischemia Followed by 30 min
of Reperfusion*
Total
(no .)
Hearts in VF
(no .)
Hearts in SR
(no .)
Total
(no .)
Hearts in VF
(no.)
Hearts in SR
(no
.)
Control
109
97 12
Control 24
12
12
Glibenclamide (Iumol/liter)
1
63 51
12
Glibenclamide (AmoUliter)
1
18 6 12
3
22 10
12 3
14 2 12
10 29
17 12
10
14
2
12
30
35 23
12 30 20
8 12
Cromakalim (umol/hter)
I 118
106 12
Cromakalim (pmol/liter)
1
26 14 12
3 120
108 12
3 29
17
12
10
120 120
0 10 30
30 0
30
120
do 0 30
30 30 0
Total
(no
.)
Hearts in VF
(no .)
Hearts in SR
(no .)
Control 48
36 12
Glibenclamide (Amouliter)
1 31 19 12
3
17 5 12
10
23 II 12
30 28 16
12
Cromakalim (AmolAiter)
1
46 34 12
3
50 38 12
10 50
49 1
30
50 50
0
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Table 4
. Effects of Glibenclamide and Cromakalim on Myocardial Function After 30, 40 and 50 min of Normothernnic Global Ischemia
Followed by 30 trip of Reperfusion in Nonfibrillating Hearts
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*p < 0.05 . Values presented are mean value ± SEAR
; comparisons were made with the untreated time-matched control hearts . A F
= aortic flow ; CF =
coronary flow ; HR heart rate ; ISA = ischemia ; LVDP = I& ventricular developed pressure
; LV dP/dt max = first derivative of left ventricular developed
pressure ; ALVEDP relative increase in left ventricular end-diastolic pressure .
untreated (n = 12)
HR (beats/min)
318 ± 6
319±7
300 8
295 t 9
282 ± 10
CF (milmin) 21 .0 ± 1 .5 22
.2 ± 1
.7
23.2 1 .6
nA 1 .1
20.0 ± 0.8
AF (ml/min)
39.0 ± 1 .4 40 .5 ± 1 .2
13 .5 1 .4
111 0 .8
8 .9 ± 0,7
LVDP (kN) 16
.5 ± 0.4 16 .5 ± 0.3
15 .9 0 .5
6 .4 0 .3
5 .1 0 .3
LV dFidt max (kPaiS) 485 ± 28
490 ± 24 460 18
214 18
1% 14
ALVEDP (kN)
0.1 ± 0.02
0 .1 ± 0 .02 0.8 0 .05
11 0 .1
1 .7 0.2
Glibenclamide (u = 12)
pmoUliter
HR (beats/min) 310 ± 8
317 ± 5 294 ± 6
283 8
271 ± .0
CF (66n) 22.0±0.8 20.9±1
.3 21.5±1 .7
20.8±I .5 19.2±1
.0
AF (ml/min)
41 .6±1 .9 42 .0°°±2 .0
14.6±0 .9
11 . 5±1 .8 9.2¢0
.8
LVDP IN 15.9±0
.4 16 .0±°0 .4
15.6±0
.3
7.1±0 .4
53 14
LV 00 max (k NA) 500± 31
500 ± 31 441 ± 26
232 21
176 14
ALVEDP (kPa) 0.1±0.02 0
.1±0.02 0.7±0.05
L1 -±0 .1 1 .5±0
.1
3 pundliter
HR (beats/min)
321±9 309±8
305±6 300±7
290±9
CF (111PInin) 23.4±1
.4 21 .7±0 .8 215±0.9
21.7±0.7
20.5±0.9
AF (ml/min) 38.9±1 .7
39.6±1 .1 12.9±1 .0
11.5±1 .2 7.9±0
.6
LVDP (kAX) 16.2±0
.3
16
.7±0.4 15.8±0.4
10
.9±0
.5* 47 ± TY
LV dP/(It max (kPa/s) 473 ± 20
485 ± 26 452 ± 17 386 ± 20*
354 16*
ALVEDP (kN) 0.1±0.02 0.1±0.02
0.3±0.01* 0.4±0.1*
00
.4±0 .1
1,
10 mmol/liter
HR (beats/min) 311 ± 7
308 ± 9 291 ± 8
290 ± 6 288 ± 10
CF (mllmin) 21 .3±1 .0 20.7±0.7
20.5±1
.4
20.2±1 .1 19.3±1
.4
AF (ml/min) 42.1±1 .8 39.8±1 .6 11
.9±1
.0
9 .4 -±0 .6 7.8±0
.8
LVDP AN 16.0±0.3 16.0±0.3
15.3±0
.4
9.9±0.3* So ±0 .4*
LV 00 max (kPals)
452 ± 18 440 ± 20 436 ± 24 348 ± 17*
306 ± 20 *
ALVEDP (kN) A! ±0.02
0.1 ±0
.02
0.4±0
.1*
0.4±0 . V 0.8±0
.2*
30 jumol/liter
HR (beats/min) 309 ± 8 320 ± 7
289 ± 9 286 ± 5 274 ± 11
CF (mllmin) 22
.0±0.8 19 .0 -±0.6* 19.2±1 .0* 18.7±0.9* 17
.6±1.0*
AF (mllmin) 39.7±1,4
33.2±1
.0*
8.6±0.6* 7.8±0.7* 7.4±0 .9*
LVDP (kRA) 15.8±0.5 14.8±0.4*
110
.0!- 0 .6*
11 ±0.3* 3.5±0.3"-
LV dP/dt max (kPals) 443 ± 25 362 ± 13* 288 12*
10 ± 12* 145 ± W"
ALVEDP IN 0.1±0.02 0.3±0.05*
1 .3±0
.1* 1 .6 -±0
.2* 23 ± W?
Cromakalim (n = 12)
1 Amol/wer
HR (beats/min) 310 ± 7
311 ± 6 296 ± 8 2 88 ± 6 25 ± 9
CF (mllmin) 21 .4±0.9 24
.5± 1,0* 25 .8± 1
.2*
25
.6± IT 24.6±0.9*
AF (m/min) 41.2±1
.5
40.7±1.6
12.8±0
.8
11
.0±1.2 9.7±0 .5
LVDP (kN) 15.8±0.5 15.8±0.5 15.3±0.4 5.9±0.3 61 ± 15
LV dP/dt max (kPals) 456 ± 17 441 ± 19 435 ± 23 249 ± 19 210 ± 24
ALVEDP (kN) 0.1 ±0.02 0 .1 ±0 .02 0.9±0
.05 1 .0±0 .t 1 .5±0.1
3 Amol/liter
HR (beats/min) 315 t 6 313 7 293 ± 7
29 ± 7 25 8
CF (mNW) 20A ± 1
.0
25
A
1 .1 *
26
.7 ± 1 .4* 26 .4 ± 1 .1 * 24 .8 1 .4*
AF (mllmin) 39.8±2.0 39 .0 1 .3 13 .8± 1 .0
9.6±0.7 8 .0 0 .7
LVDP AN 16.8±0.4 16.0+0.3 15.6±0
.5 6.7±0.3 4 .7 0.4
LV dP/dt max (kPals) 432 ± 20 456 28 447 ± 20
228 ± 21 185 12
ALVEDP (kN) 0.1±002 0.1±0.02 0.6±0
.1 1.3±0 .1 15 0.2
Preischemia
After 30 rain ISA,
After 40 min ISA,
After 50 win ISA,
Followed by
Followed by
Followed by
Before Drug After Drug
30 min Reperfusion
30 min Reperfusion
30 min Reperfusion
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Figure 3. Representative phosphorus-31 nuclear magnetic reso-
nance spectra drug-free hearts (a) and hearts treated with glibencla-
mide (3 umolAiter) (b) obtained within 3 min, respectively, under
aerobic control conditions (A) and after 30 (8), K) A and 50 min (D)
of normothermic global ischemia followed by reperfusion . Spectra
show the peaks of cc, 0-, y-adenosine triphosphate (ATP), creatine
phosphate (Crl?), inorganic phosphate (P j ) and l-phenyl-l-
aminomethylene diphosphonate as reference (R). Left ventricular
developed pressure (LVDP) is also shown beside each spectra .
liter of cromakalim (Tables I to 3), myocardial function
variubles could not be recorded.
rus-31 NMR studies. Figure 3 depicts represen-
tative phosphorus-31 NMR spectra obtained from drug-free
hearts (top) during aerobic perfusion (A) and after 30 (B),
40 (C) and 50 (D) min of global ischemia followed by 30 min
of reperfusion in nonfibrillating hearts . Left ventricular
developed pressure is shown in each instance . Thus, after
30 min of ischemia followed by 30 min of reperfusion (B in
Fig. 3a), despite the low myocardial ATP content, left
ventricular developed pressure reached its preischemic con-
JACC Vol . 23, No . 2
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trol value, indicating a dissociation between myocardial ATP
content and myocardial contractility. After increasing the
duration of ischemia to 40 min (C in Fig . 3a) and after 30 min
of reperfusion, myocardial ATP content was very low, and
myocardial contractility was reduced. Thus, a dissociation
between myocardial ATP content and myocardial contrac-
tility was not detected . Fifty minutes of ischemia followed
by 30 min of reperfusion (D) resulted in a further reduction
in both myocardial ATP and contractile activity. Creatine
phosphate content was completely recovered, or even
"overshot," after 30 min of ischemia followed by reperfu-
sion (B in Fig . 3a) . After the extension of ischemia to 40 or
50 min, reperfusion failed to recover creative phosphate
content, and an accumulation of inorganic phosphate con-
tent was detected (C and D in Fig . 3a) .
Glibenclamide (3 AmOl/liter) improved myocardial ade-
nosine triphosphate content and c -, ,.ntractility of the myocar-
dium after 30, 40 and 50 min of reperfusion (Fig . 3b), and a
dissociation between myocardial ATP and contractility was
not observed. Although myocardial ATP and contractility were
significantly improved on reperfusion in the glibenclamide-
treated groups (Fig. 3b) compared over time-matched con-
trol values (Fig . 3a), an accumulation of inorganic phosphate
content was detected in the drug-treated ischemic/reperfused
myocardium .
In hearts treated with l or 2 umol/liter of cromakalim,
significant changes were not detected either in tissue ATP,
creatine phosphate, inorganic phosphate or contractility
compared with the drug-free values . Therefore these spectra
are not shown . Neither glibenclamide (1 or 3 Amol/liter) nor
cromakalim (I or 3 tLmoUliter) influenced myocardial ATP,
creatine phosphate and intracellular pH under aerobic con-
ditions (Table 5). An episode of myocardial ischemia re-
sulted in the rapid breakdown of myocardial ATP and
creatine phosphate in the control group ; thus, myocardial
ATP and creatine phosphate content were not detectable
after 12 and 6 min of global ischemia (Table 5) . Glibencla-
mide (3 Amol/liter) significantly improved myocardial ATP
content, whereas cromakalim (3
AmOyliter)
increased the
breakdown of ATP during myocardial ischemia . Myocardial
creatine phosphate content and intracellular pH were not
influenced by glibenclamide and cromakalim . Intracellular
pH decreased during the 1st 12 min and never declined to
<pH 6 during the further course of myocardial ischemia in
untreated and treated groups (Table 5) .
On reperfusion (Table 5), after 30 min of global ischemia,
glibenclamide (3 Amol/liter) significantly improved the re-
covery of myocardial ATP, whereas cromakalim worsened it
compared with the drug-free control values . Myocardial
creatine phosphate content was not significantly increased or
decreased with respect to drug-free values during reperfu-
sion in either glibenclamide-treated or cromakalim-treated
hearts (Table 5) . Intracellular pH immediately returned to
preischemic control values in all groups, and pharmacologic
interventions did not affect this variable (Table 5) . After the
9th min of reperfusion, further improvements or changes in
JACC Vol. 23, No. 2
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myocardial ATP and cratine phosphate content and pH
were not observed in the control or treated groups ; there-
fore, I= data am not shown .
iscussion
rhythmias and ATP-sensitive potassium channel openers
•
	
and blockers. Although arrhythmias were first described by
visual observation some 100 years ago (19), before 1982 only
oral quinidine, procainamide, disopyramide and propranolol
were available for the clinical treatment of ventricular ar-
rhythmias . Since 1982, the armamentarium of antiarrhyth-
•
mic drugs has been extended in clinical studies, and, re-
cently, the use of ATP-sensitive potassium channel openers
as antihyperiensive agents has been introduced for the
treatment of ischemia/reperfusion-induced injury in experi-
mental studies. Carlsson et al . (20) showed that pinacidil and
two of its analogues suppressed arrhythmias caused by
repolarizalion abnormalities in a rabbit model of the long QT
syndrome in vivo and in rabbit ventricular tissues in vitro .
These ATP-sensitive potassium channel activators were
shown to be highly effective in suppressing clofilium-induced
polymorphous ventricular tachyarrhythmias in vivo and
clofilium-induced early afte rdepol arizat ions andl triggered
•
activity in vitro. This study provides further evidence in
support of the hypothesis that marked action potential
• prolongation and early afterdepolarization-induced triggered
activity are important factors contributing to the manifesta-
tion of polymorphous ventricular tachyarrhythmias, such as
torsade de pointes. The findings suggest that activation of
ATP-sensitive p 'assium channel may provide a novel ther-
•
apeutic approach in the treatment of this type of arrhythmia,
which is often seen in patients with the acquired long QT
• syndrome . Pinacidil and cromakalim have been shown to
abolish early afterdepolarization and triggered activity in
canine Purkinje fibers exposed to quinidine, cesium or
•
sematilide (4) . Because ATP-sensitive potassium channel
•
openers possess an action that may involve an enhanced
potassium ion efflux from the myocardium (21,22), one might
hypothesize that pharmacologic interventions that enhance
the loss of potassium ion through ATP-sensitive potassium
channel would be arrhythmogenic . Furthermore, it could be
speculated that the pharmacologic enhancement of arrhyth-
mogenesis, secondary to the facilitation of an outward
potassium current, would be manifested electrophysiologi-
cally in the presence of an acute ischemic/reperfusion event
superimposed on a myocardial substrate involving recent
myocardial damage .
The aim of the present study, in part, was to evaluate the
electrophysiologic characteristics, including the antiarrhyth-
mic properties, of glibenclamide and cromakalim in such a
model of ischemia/reperfusion-induced injury . Glibencla-
mide, an ATP-sensitive potassium channel blocker, signifi-
cantly reduced the incidence of reperfusion-induced arrhyt)
mias, whereas cromakalim, an ATP-sensitive potassium
channel opener, failed to reduce the incidence of such
6 C= C
+1 +1 +1 +1 41 +1 +1 +1 +1 +1 +1 +1
5~-
84
9! ~~ ~~ Z
00
+1
+1 +1
+1 +1 +1
+1 +1 +1 2
0
0 .2
16-1 Na
+1 +1 +1 +1 +1 +1 +1 +1 +1 +1
IL
U
11
.9
+1 41 +1 -H +1 +1 +1 +1 +1 +1 +1
0
U
11
ci_
+i H +1 +1 +1 +1 +1 +1 +1
G 2
2
I S S 8 Z3 . q
~2
+1 +1 it +1 it
+1 +1 it it +1 it
0 is U 81 Us A P". 4 -g
0
C:
C C
+1 +1 +1 +1 +1
+1 +1 1-1 +1 +1 +1 41
.17-0.
ri I
- lo ~q n R Nom=22 'I
li oR
rrr- 80080 '0
eb
-
lb
+1 +1 +t +1 +1
+1
+1 +1 +1
CO
E
U
7;
zL
M
U
+1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1
S
-E
Q j il Q S Q 1! Yl 30 NI
C GC O=©074 6 6 =56 =.'_:~ c5
A
=
5
+1 +1 +1 +1 +1
+1 C +1 +t +1 +1 +1 -E-
<
T Vl'c'c w,
E
+1 +1 +1 +1 +1
+1
+1 +1 +I 2
7a
ti.
U
tn
41
cl
'n ' q- 'n v) m 'n' v9M 'DAN
+1 +1 +1 +1 +1 +1 +1 +1 41 +1 +1 +1
E 'Q
+1 11
+1 +1 +1 +1
+1 41 +1 +1 +1 +1 +1 -. g
U
M
M ^N
3~1
d
+1 +1 +1 +1 41
+1
+1 +1 +1
JM
E
cc
U ,m
1
a a V11
~a e
-D _0
0
+1 +1 +1 +1 +1 +1 +1 +1
+1 +1 +1
N II
00
V L4
4 'I
4
494
	
TOSAKI AND HELLEGOUARCH
POTASSIUM CHANNELS IN
ISCHEMIA/REPERFUSION
arrhythmias . in our previous studies (17,18) in a subset of
hearts unresponsive to reperfusion-induced arrhythmias,
cromakalim or pinacidil treatment was associated with a
greater incidence of reperfusion arrhythmias . These pro-
arrhythmic effects of ATP-sensitive potassium channel
openers were also reflected in a maldistribution of myocar-
dial ions in ischemic/reperfused hearts. In agreement with
our data presented herein, Kantor et al. (23) and Billman et
al. (9) have shown that ATP-sensitive potassium channel
blockers inhibit both ischemia/reperfusion-induced myocar-
dial potassium ion loss and the development of ventricular
fibrillation . These observations provide evidence that potas-
sium ion loss resulted from opening of ATP-sensitive potas-
sium channel and that the potassium ion efflux was related to
the onset of ventricular fibrillation . As a result, it is very
difficult to understand how an ATP-sensitive potassium
channel opener, secondary to the facilitation of an outward
potassium ion current via ATP-sensitive potassium channel
(3,4), could be considered to exercise an antiarrhythmic
action in the presence of an acute ischemic event. Clinical
evaluation of ATP-sensitive potassium channel openers in
patients with essential hypertension suggests therapeutic
efficacy with an incidence of dose-related side effects of
edema formation, palpitation and ventricular tachycardia
(24,25) .
My function and ATP-sensitive potassium channel
r rmrs and b8 ers, The drugs used in our study altered, in
part, myocardial function . Thus, heart rate was not signifi-
cantly changed in either glibenclamide- or cromakalim-
treated hearts before the induction of ischemia and during
reperfusion with the time-matched control values . Cro-
makalim decreased, but glibenclamide did not change, cor-
onary resistance (in its optimal antiarrhythmic concentra-
tions, 3 to 10 µmot/liter), indicating that changes in coronary
flow rate are not responsible for drug-induced alterations in
the incidence of reperfusion-induced arrhythmias . The re-
covery of myocardial contractility (left ventricular devel-
oped pressure) was improved with 3 and 10 µmolIliter of
glibenclamide during reperfusion, whereas a higher concen-
tration of the drug (30 µmol/liter) significantly reduced the
recovery of postischemic contractility compared with the
drug-free control values. Because of the proarrhythmic
action of cromakalim, higher concentrations of the drug
(>3 µmollliter) made it impossible to study myocardial
function in our model system, and lower concentrations of
the drug (<3 µmol/liter) did not result in any improvement in
myocardial contractility during the postischemic period . The
beneficial effects of glibenclamide on myocardial function
may be attributed to its "potassium-conserving" effect (18) .
Studies using different in vivo and in vitro models of ischemia)
reperfusion show there is a critical time window during
which reperfusion of the ischemic myocardium will result in
a full recovery of cardiac function . The length of this time
window varies somewhat depending on the model of isch-
emia (8) and can be modified by different interventions .
Unfortunately, we were not able to find this window with
JACC Vol . 23, No . 2
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regard to the protective effects of cromakalim in our studies
even though the duration of ischemia was varied, and different
concentrations of cromakalim were used .
High energy phosphates and ATP-sensitive pot Ium
channel openers and blockers. Many studies have shown a
close correlation between ATP-sensitive potassium channel
blockers or openers and myocardial potassium content, but
to our knowledge the relation between these drugs and
myocardial ATP content has not been studied, although
ATP-sensitive potassium channel blockers or openers may
have a direct or indirect effect on high energy phosphate
content during ischemia and reperfusion . The correlation, if
any, is not necessarily mutually exclusive, and additional,
still unidentified, effects may play a role as well . The present
study was also undertaken to define the effects of an ATP-
sensitive potassium channel blocker and opener on myocar-
dial energy metabolism using
3i
P-NMR spectroscope during
ischemia and reperfusion in the isolated hearts . We defined
changes in ATP, creatine phosphate and inorganic phos-
phate content as well as intracellular pH throughout periods
before and during ischemia and during reperfusion in hearts
in which myocardial performance was altered by supplying
an ATP-sensitive potassium channel blocker or opener . In
addition, we studied the time course of ischemia (30, 40 and
50 min) followed by reperfusion and the recovery or disso-
ciation of myocardial contractility in untreated and drug-
treated hearts .
Ischemia led to the breakdown of ATP and creatine
phosphate, accumulation of inorganic phosphate and devel-
opment of moderate acidosis, as deduced from an upfield
shift c,,f the inorganic phosphate peak in the
31
P-N R
spectrum. Untreated hearts reperfused after 30 min of isch-
emia showed a moderate depression (not significant) of
cardiac contractility and a marked depletion of ATP that
persisted throughout the reflow period . Thus, the relation
between left ventricular developed pressure and myocardial
ATP content in reperfused untreated hearts revealed the
absence of a linear relation between these two variables .
These results are entirely consistent with earlier data (26)
and demonstrate that the level of myocardial ATP is signif-
icantly dissociated from cardiac contractile function after a
relatively short period (25 to 30 min) of ischemia . Thus, our
results indicate that an initial decrease in myocardial ATP
content has no effect on recovery of contractility, suggesting
that ATP levels have no immediate bearing on the contractile
status of depressed hearts and that the improved recovery of
left ventricular developed pressure (96 ± 3%) could be
related to creatine phosphate production (I I 1 ± 6%) during
reperfusion . In a different setting, findings in other studies
have also documented a dissociation between myocardial
ATP levels and recovery of myocardial function (left ven-
tricular developed pressure) in postischemic reperfused
hearts (27,28) . On extension of the duration of myocardial
ischemia to 40 and 50 min, a dissociation between myocar-
dial ATP content and contractility was not observed, and
both myocardial ATP content and contractility showed a
JACC Vol . 23, No . 2
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linear reduction, This, we can conclude that a dissociation
exists between myocardial ATP content and contractility if
the duration of ischemia is <30 min .
In the glibenclamide-treated group (3 Xtrnol1liter), myocar-
dial ATP and creatine phosphate content and contractility
were significantly improved during reperfusion, and a disso-
ciation between myocardial ATP content and contractility
was not observed . Furthermore, cromakalim, an ATP -
sensitive potassium channel opener, failed to improve myo-
cardial contractility and high energy phosphate content in
ischemic/reperfused hearts . These studies suggest that the
blockade of ATP-sensitive potassium channels improves
the recovery of postischemic function in our model, whereas
the opening of ATP sensitive potassium channels does not
improve or may worsen it . No work has specifically ad-
dressed the mechanism of ATP-sensitive potassium channel
blockers in increasing myocardial high energy phosphate
content, and it therefore remains incompletely character-
ized. The present study does not permit a full assessment of
the cellular mechanisms responsible for the preservation of
high energy phosphate in glibenclamide-treated hearts, but
one possibility is the "indirect" inhibition of calcium ion
accumulation in myocardial cells. The profile of potassium
ion loss and increased sodium ions is in accord with inhibi-
tion of sarcolemmal sodium-potassium adenosine triphos-
phatase activity (29) . Elevation of sodium ions preceded the
elevation of calcium ion , . in the mitochondria ; a similar trend
was evident in the cytoplasm . These observations are con-
sistent with the operation of the sodium-potassium ex-
changer in the mode of calcium ion influx for sodium ion
efflux (30) . The blockade of potassium channels may reduce
sodium ion inflow concomitantly with the release of calcium
ions from the sarcoplasmic reticulum and, consequently,
respiration is increased in the mitochondria, improving ATP
resynthesis . This effect might be reversed by ATP-sensitive
potassium channel openers .
Limitations of the model. The model in our studies has
several limitations . Cardiac muscle relaxation during normo-
thermic global ischemia is independent of load and is primar-
ily determined by the intracellular processes that influence
the rate and extent of force inactivation, which can include
the ATP-dependent rate and calcium ion sequestration ca-
pacity of the sarcoplasmic reticulum. The interpretation of
results must of course be limited by our observations in the
guinea pig heart and by the fact that we used an isolated
preparation. The immediate extrapolation of our results,
obtained in isolated guinea pig hearts, to an actual clinical
situation should be viewed with some caution because of the
absence of blood and its elements (e.g., platelets and leuko-
cytes) in our model system and possible interspecies differ-
ences in myocardial metabolism . The use of th, : isolated
perfused heart, although offering the advantage of permitting
study of direct cardiovascular responses independent of
various peripheral factors, has the disadvantage of being
denervated and perfused with asanguineous solutions . Fur-
thermore, 31P NMR spectroscopy is not sensitive enough to
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measure very low concentrations of high energy phosphates .
Thus, if myocardial ATP and creatine phosphate contents
decrease to <20% to 25% of preischernic control values,
detection of high energy phosphates, because of the sensi-
tivity of the method, is not possible (Fig . 5) .
Conclusions . Despite these limitations, the ATP-sensitive
potassium channel antagonist glibenclamide significantly
protected the heart against reperfusion-induced ventricular
fibrillation and ventricular tachycardia in a model of ischemia/
reperfusion in which the hearts were susceptible to malig-
nant arrhythmias . This protection was reflected in the im-
provement of myocardial function and the recovery of the
energetic state of the myocardium. Cromakalim, an ATP-
sensitive potassium channel agonist, failed to reduce the
incidence of reperfusion-induced arrhythmias and aggra-
vated myocardial dysfunction . Therefore, the treatment of
postinfarction patients, who are known to be at high risk for
sudden coronary death, with ATP-sensitive potassium chan-
nel openers may be of particular concern .
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